Senti Biosciences officer reports tax-share withholding

Senti Biosciences executive Kanya Rajangam reported a routine tax-related share disposition.

Rhea-AI Filing Summary

Senti Biosciences executive Kanya Rajangam reported a routine tax-related share disposition. On this filing, 10,757 shares of common stock were withheld by the company to cover income tax obligations tied to vested restricted stock units, and not sold on the open market. After this withholding, Rajangam directly holds 74,843 common shares.

Insider Trade Summary

Exercise Price or Tax Liability: 10,757 shares

Exercise Price or Tax Liability 1 txn

Insider Rajangam Kanya

Role Pres. & Chief Med. & Dev. Off.

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	10,757	$0.00	$0.00

Holdings After Transaction: Common Stock — 74,843 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Senti Biosciences (SNTI) insider Kanya Rajangam report on this Form 4?

Kanya Rajangam reported that 10,757 Senti Biosciences common shares were withheld by the company to satisfy income tax obligations on vested restricted stock units, and these shares were not sold in the open market.

Was the SNTI Form 4 transaction an open-market sale of shares?

No, the Form 4 specifies the 10,757 Senti Biosciences shares were withheld by the issuer for tax withholding and remittance, and the footnote clarifies this does not represent an open market sale of stock.

How many Senti Biosciences (SNTI) shares does Kanya Rajangam hold after the reported transaction?

Following the tax-withholding disposition of 10,757 shares, Kanya Rajangam directly holds 74,843 shares of Senti Biosciences common stock, as shown in the post-transaction ownership column of the Form 4 filing.

What is the transaction code used in the Senti Biosciences (SNTI) Form 4 for Kanya Rajangam?

The Form 4 uses transaction code “F,” which indicates shares were disposed of to pay an exercise price or tax liability. Here it reflects company withholding of 10,757 shares to cover income tax on restricted stock units.

Does the SNTI Form 4 for Kanya Rajangam indicate any stock option exercises?

No, the transaction summary shows no derivative exercises, and the only reported movement is a tax-withholding disposition of 10,757 common shares relating to restricted stock units, not an option exercise event.

Is the Senti Biosciences (SNTI) insider transaction considered routine compensation-related activity?

Yes, the Form 4 describes a routine compensation-related event where 10,757 shares from restricted stock unit vesting were withheld by the issuer to satisfy tax obligations, rather than representing a discretionary market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rajangam Kanya

(Last) (First) (Middle)

C/O SENTI BIOSCIENCES, INC.

2 CORPORATE DRIVE FIRST FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Senti Biosciences, Inc. [ SNTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres. & Chief Med. & Dev. Off.

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		F		10,757(1)	D	$0	74,843	D(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale.

Remarks:

	/s/ Robert Cutler, attorney-in-fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.